Program
siplizumab
Also written as “MEDI-507”, “TCD601” and “Siplizumab”.
Its studies are mostly in Graft vs Host Disease · Psoriasis · Amyotrophic Lateral Sclerosis · Diabetes Mellitus, Type 1 · Kidney Diseases, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ITB-Med | 92 open or running | phase 2since Mar 12, 2020 | Mar 12, 2020 | Mar 28, 2028phase 2 · NCT07508787 |
| AstraZeneca | 80 open or running | phase 2since Sep 13, 2005 | Mar 11, 2005 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2005First study: phase 1 study in LymphomaNew to AstraZenecaAstraZeneca · NCT00105313 · 80 enrolled · United States
- Jul 22, 2005Phase 1 study in Lymphoproliferative DisordersAstraZeneca · NCT00123942 · 31 enrolled · United States
- Sep 13, 2005Phase 2 study in PsoriasisAstraZeneca · NCT00192452 · 120 enrolled · United States
- Oct 4, 2007Phase 2 study in Plaque PsoriasisAstraZeneca · NCT00540618 · 420 enrolled · United States, Canada
- Dec 9, 20084 phase 1 studiesAstraZeneca · NCT00806208, NCT00807794, NCT00806728 and 1 more
- Mar 12, 2020ITB-Med's first study: phase 2 study in Kidney TransplantationNew to ITB-MedITB-Med · NCT04311632 · 13 enrolled · United States
- Mar 14, 20212 phase 2 studies in Kidney TransplantationITB-Med · NCT04803058, NCT04803006
- Dec 20, 2022Phase 2 study in Renal TransplantationITB-Med · NCT05669001 · 76 enrolled · United States
- Aug 25, 20232 phase 2 studiesITB-Med · NCT06025110, NCT06019507
- Apr 10, 2024Phase 2 study in Kidney TransplantationITB-Med · NCT06365437 · 33 enrolled · Austria, Spain, Sweden
- May 6, 2024Phase 1 study in Amyotrophic Lateral SclerosisITB-Med · NCT06453668 · 7 enrolled · Sweden
- Mar 11, 2026Phase 2 study in Rejection, PsychologyITB-Med · NCT07508787 · 120 planned · United States, Brazil, Spain
Ahead
- Mar 28, 2028Primary completion: phase 2 study in Rejection, PsychologyITB-Med · NCT07508787
TargetBeta
“T-cell surface antigen CD2 inhibitor”ChEMBL 37, by rule
Other programs on CD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 3 |
| Anti-ULBP2/5/6/CD3/CD2 Trispecific T-cell Engager EVOLVE104rule | evolveimmune-united-inc | phase 1 | 1 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07508787Rejection, Psychology · United States, Brazil, Spain | 2 | Recruiting | ITB-Med | Mar 28, 2028 | 120 |
| NCT06453668Amyotrophic Lateral Sclerosis · Sweden | 1 | Terminated | ITB-Med | Jul 2, 2026 | 7 |
| NCT06365437Kidney Transplantation · Austria, Spain, Sweden | 2 | Terminated | ITB-Med | Dec 11, 2024 | 33 |
| NCT06025110Diabetes Mellitus, Type 1 · Belgium, Italy, Spain and more | 2 | Terminated | ITB-Med | Jul 24, 2025 | 9 |
| NCT06019507Liver Transplantation · Sweden | 2 | Active, not recruiting | ITB-Med | Jun 2026 | 12 |
| NCT05669001Renal Transplantation · United States | 2 | Completed | ITB-Med | Apr 10, 2026 | 76 |
| NCT04803058Kidney Transplantation · United States, South Korea | 2 | Terminated | ITB-Med | Feb 17, 2026 | 7 |
| NCT04803006Kidney Transplantation · United States | 2 | Terminated | ITB-Med | Oct 30, 2025 | 4 |
| NCT04311632Kidney Transplantation · United States | 2 | Completed | ITB-Med | Oct 3, 2023 | 13 |
| NCT00813618Graft vs Host Disease · United States | 1 | Completed | AstraZeneca | Jun 2004 | 10 |
| NCT00807794Kidney Diseases · United States | 1 | Completed | AstraZeneca | Nov 1997 | 13 |
| NCT00806728Neoplasms · United States | 1 | Completed | AstraZeneca | Nov 1998 | 17 |
| NCT00806208Graft vs Host Disease · United States | 1 | Completed | AstraZeneca | Jan 2000 | 34 |
| NCT00540618Plaque Psoriasis · United States, Canada | 2 | Completed | AstraZeneca | 420 | |
| NCT00192452Psoriasis · United States | 2 | Completed | AstraZeneca | 120 | |
| NCT00123942Lymphoproliferative Disorders · United States | 1 | Terminated | AstraZeneca | 31 | |
| NCT00105313Lymphoma · United States | 1 | Terminated | AstraZeneca | 80 |
How it is read
Names in the registry
- “MEDI-507”, 20 entries
- “TCD601”, 8 entries
- “Siplizumab”, 1 entry
Conditions, from the studies’ own filings
- Graft vs Host Disease, 2 studies
- Psoriasis, 2 studies
- Amyotrophic Lateral Sclerosis, 1 study
- Diabetes Mellitus, Type 1, 1 study
- Kidney Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.